KAT2A and neuroblastoma: On the basis of our findings using the PROTAC degrader GSK-699-1, combined loss of KAT2A/KAT2B reduced neuroblastoma proliferation and induced transcriptional and epigenetic changes that are consistent with TADA2B degradation.